Clopidogrel Tablet
Product Images NDC 50090-7466

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50090-7466). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clop02-a (Clop02 A)

A horizontal error bar chart illustrating the effect of co-administered proton pump inhibitors (PPIs) Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on active metabolite AUC. The X-axis shows change relative to Plavix administered alone, ranging from 0.4 to 1.4, with each PPI effect depicted with a point estimate and 90% confidence intervals.*

FDA Label Image

Clop03-a (Clop03 A)

A line chart showing cumulative event rate (%) over 12 months of follow-up for cardiovascular death, myocardial infarction, and stroke. It compares placebo plus aspirin and clopidogrel plus aspirin groups, with the clopidogrel group showing a lower cumulative event rate. The chart notes other standard therapies were used as appropriate, and includes a p-value of 0.00009.*

FDA Label Image

Clop04-a (Clop04 A)

A forest plot showing hazard ratios with 95% confidence intervals for various subgroups comparing Clopidogrel versus placebo. Subgroups include age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction (MI), previous stroke, heparin/LMWH use, aspirin dosage, GPIIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. The plot displays the number of subjects and event percentages for Clopidogrel and placebo groups, indicating which treatment is favored for each subgroup and overall.*

FDA Label Image

Clop08-a (Clop08 A)

A line graph depicting cumulative event rate percentages for fatal or non-fatal vascular events over 36 months of follow-up. Two lines represent the event rates for aspirin and clopidogrel, showing the comparison of vascular event rates between these two treatments during the study period.*

FDA Label Image

Clop_01 (Clop 01)

Chemical structure of Clopidogrel Bisulfate, showing its molecular framework including a thiophene ring, a bicyclic ring system with a nitrogen atom, an ester functional group, a chlorophenyl ring, and a sulfate group (H2SO4).*

FDA Label Image

Clop_05 (Clop 05)

A Kaplan-Meier curve showing the percentage of patients dead before first discharge over 28 days since randomization for placebo and clopidogrel tablet groups. The chart indicates 8.1% deaths in the placebo group and 7.5% deaths in the clopidogrel group, with a 7% proportional risk reduction (p = 0.03). Both groups received aspirin.*

FDA Label Image

Clop_06 (Clop 06)

A Kaplan-Meier curve chart showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization. It compares outcomes for patients receiving placebo versus Clopidogrel tablets, indicating a lower event rate for Clopidogrel with a 9% proportional risk reduction (p = 0.002). The x-axis represents days since randomization, and the y-axis represents percentage with events.*

FDA Label Image

Clop_07 (Clop 07)

A forest plot showing subgroup analysis of outcomes comparing Clopidogrel Tablets 75 mg to placebo. Subgroups include gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot displays odds ratios with 95% confidence intervals, indicating relative favoring between Clopidogrel Tablets and placebo across subgroups, with an overall odds ratio provided.*

FDA Label Image

Clop_09 (Clop 09)

A forest plot comparing hazard ratios with 95% confidence intervals for Clopidogrel Tablets versus Aspirin across qualifying conditions including Stroke, MI (Myocardial Infarction), and PAD (Peripheral Artery Disease), as well as an overall summary. The X-axis represents hazard ratios ranging from 0.6 to 1.3, with markers showing favorability towards either Clopidogrel or Aspirin tablets.*

FDA Label Image

Label Image (Lbl500907466)

Label for CLOPIDOGREL 75 mg oral tablets from A-S Medication Solutions. The label states each film-coated tablet contains 97.875 mg of clopidogrel bisulfate equivalent to 75 mg of clopidogrel base. The package contains 30 tablets and storage instructions specify to keep below 77 degrees Fahrenheit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.